Skip to main content

Bionomics Limited (BNOX)

Bionomics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-6.54M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BNOX

Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS. The α7 nicotinic acetylcholine receptor (“α7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance. Utilizing our expertise in ion channel biology and tr...

IndustryBiotechnology
Founded1996
CEOErrol De Souza, Ph.D.
Employees7
Stock ExchangeNASDAQ
Ticker SymbolBNOX
Full Company Profile

Financial Performance

Financial Statements

News

Australia-listed CNS biotech Bionomics files for a $25 million US IPO

Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, filed on Monday with the SEC to raise up to $25 million in an initial public offering.

1 week ago - Renaissance Capital

Bionomics IPO Registration Document (F-1)

Bionomics Limited has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

2 weeks ago - Simply Wall St

Bionomics gets FDA approval for trial of social anxiety disorder treatment

The US FDA has cleared Bionomics' IND application to commence the Phase II trial of its BNC210 to treat social anxiety disorder (SAD).

1 month ago - Clinical Trials Arena